Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Van Uden E, Mallory M, Veinbergs I, Alford M, Rockenstein E, Masliah E. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J Neurosci. 2002 Nov 1;22(21):9298-304. PubMed Abstract, View on AlzSWAN

  
Comments on Paper and Primary News
  Primary News: It’s a RAP—Loss of LRP Increases Amyloid Deposition in Mice

Comment by:  G. William Rebeck
Submitted 2 November 2002  |  Permalink Posted 2 November 2002

Over the last 10 years, numerous studies have indicated that the low-density lipoprotein receptor-related protein (LRP) may be important for the pathogenesis of Alzheimer's disease. These include studies showing that LRP can internalize membrane-bound forms of the amyloid precursor protein and cause increased Aβ production, and studies showing LRP can internalize Aβ bound to ApoE and α2-macroglobulin, causing increased Aβ clearance. One in vivo study that has been missing is the analysis of Aβ deposition in knockout LRP mouse models of AD. This study has not been possible, since LRP knockouts are not viable. However, Van Uden et al. took the interesting approach of studying mice that have the LRP-associated protein, RAP, knocked out. RAP is important for the maturation and trafficking of LRP, and RAP knockout mice have dramatically reduced levels of LRP. Van Uden et al. analyzed Aβ deposition RAP knockout mice crossed with APP transgenic mice. There were three possible outcomes to this study: no effect on Aβ, Aβ goes down, or Aβ goes up. The first outcome would probably not be...  Read more

  Comment by:  liu qiang (Disclosure)
Submitted 22 August 2003  |  Permalink Posted 22 August 2003
  I recommend this paper
  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:

Transgenic mice, expressing hAPP, line J9 were selected for this study.

Western Blot analysis of mouse brains were probed by rabbit polyclonal anti-RAP, 1:20,000 and anti-LAP, 1:1000, gifts from Dr.Robert Orlando (Univ. New Mexico, Alburquerque, NM); monoclonal anti-LDL-R, 1:1000 (Calbiochem) and anti-hAPP, 8E5, 1:10,000 (gift from Elan Pharmaceuticals).

Amyloid deposits were immunohistochemically stained with mouse monoclonal antibody 3D6, 1:600 (gift of Elan Pharmaceuticals). For double staining the brain sections were stained with rabbit polyclonal anti-amyloid-beta R1280 1:500 (gift from Dr. Dennis Selkoe, Brigham and Woman's Hospital, Boston, MA) and either anti-phosphorylated tau AT8, 1:100 (Innogenetics) or anti-phosphorylated neurofilaments SMI312, 1:1000 (Sternberger Monoclonals, Baltimore, MD).

Sandwich ELISA assays were used to detect Abeta(1-40) and Abeta(1-42) (Biosource).

Neurodegeneration was determined by staining brain sections with monoclonal anti-GFAP 1:500 (Chemicon) or anti-MAP2 1:10 (Chemicon).

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad